L-甲状腺素,51-48-9，生产厂家，价格-洛克化工网移动版

L-甲状腺素

中文名称：: L-甲状腺素

中文别名：: L-甲状腺素;
3,3',5,5''-四碘代-L-甲状腺原氨酸;
3,5,3',5'-四碘甲状腺胺酸;
3-[4-(4-羟基-3,5-二碘苯氧基)-3,5-二碘苯基]-L-丙氨酸;
甲状腺素左旋甲状腺素;
D-Α-生育酚;
甲四碘安,LEVOTHYROXINE;
O-(4-羟基-3,5-二碘苯基)-3,5-二碘-L-酪氨酸;
D-ALPHA-生育酚;
2-甲状腺素;
L-甲状腺激素;
2-甲状腺素 O-(4-羟基-3,5-二碘苯基)-3,5-二碘-L-酪氨酸 D-Alpha-生育酚左旋甲状腺素 3,5,3',5'-四碘甲状腺胺酸;
甲状腺素;
甲四碘胺;
左旋甲状腺素

英文名称：: L-Tyrosine,O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-

英文别名：: L-thyroxine;
tetraiodothyronine;
l-t4;
Thyrax;
L-Thyroxine;
Levothyroxine;
L-THYROXIN;
Henning;
3,5,3',5'-tetraiodothyronine;
3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine;
thyroxin;
thyroxinal;
thx;
thyroxine-binding globulin;
3,3’,5,5‘’-Tetraiodo-L-thyronine;
L-3,5,3',5'-tetraiodothyronine;
THYROXINE

CAS No.：: 51-48-9

分子式：: C₁₅H₁₁I₄NO₄

分子量：: 776.87

精确分子量：: 776.68700

PSA：: 92.78000

MDL：: MFCD00002595

EINECS：: 200-101-1

BRN：: 2228515

InChI：: InChI=1/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,123

危险品标志：: Xn:Harmful

风险术语：: R20/21/22;

安全术语：: S24/25;

分子结构式：

SDS：: 查看

L-甲状腺素制备方法及用途

制备方法

可从动物甲状腺中提取。可由3,5-二碘-L-酪氨酸为原料制取。甲状腺素的形成经过合成、贮存、碘化、重吸收、分解和释放六个过程:1. 滤泡上皮细胞从血液中摄取氨基酸,在粗面内质网合成甲状腺球蛋白的前体,继而在高尔基复合体加糖并浓缩形成分泌颗粒,再以胞吐方式排放到滤泡腔内贮存。2. 滤泡上皮细胞能从血液中摄取I-,I-经过过氧化物酶的作用而活化。3. 活化后的I-进入滤泡腔与甲状腺球蛋白结合,形成碘化的甲状腺球蛋白。4. 滤泡上皮细胞在腺垂体分泌的促甲状腺激素的作用下,胞吞滤泡腔内的碘化甲状腺球蛋白,成为胶质小泡。5. 胶质小泡与溶酶体融合,碘化甲状腺球蛋白被水解酶分解形成大量四碘甲状腺原氨酸(T4)和少量三碘甲状腺原氨酸(T3),即甲状腺素。6. T3和T4于细胞基底部释放入血。

合成制备方法

可从动物甲状腺中提取。可由3,5-二碘-L-酪氨酸为原料制取。

甲状腺素的形成经过合成、贮存、碘化、重吸收、分解和释放六个过程：1. 滤泡上皮细胞从血液中摄取氨基酸，在粗面内质网合成甲状腺球蛋白的前体，继而在高尔基复合体加糖并浓缩形成分泌颗粒，再以胞吐方式排放到滤泡腔内贮存。2. 滤泡上皮细胞能从血液中摄取I-，I-经过过氧化物酶的作用而活化。3. 活化后的I-进入滤泡腔与甲状腺球蛋白结合，形成碘化的甲状腺球蛋白。4. 滤泡上皮细胞在腺垂体分泌的促甲状腺激素的作用下，胞吞滤泡腔内的碘化甲状腺球蛋白，成为胶质小泡。5. 胶质小泡与溶酶体融合，碘化甲状腺球蛋白被水解酶分解形成大量四碘甲状腺原氨酸（T4）和少量三碘甲状腺原氨酸（T3），即甲状腺素。6. T3和T4于细胞基底部释放入血。

用途简介

生化研究；拟甲状腺素药物。

用途

生化研究；拟甲状腺素药物

L-甲状腺素物化性质

外观与性状：: 米色粉末
密度：: 2.635g/cm3
熔点：: 235 °C
沸点：: 576.3ºC at 760mmHg
闪点：: 302.3ºC
水溶解性：: insoluble
折射率：: 1.795
存储条件/存储方法：: 应充氩气密封于阴凉干燥处避光保存
稳定性相关：: 常温常压下稳定
避免光，明火，高温，
其它信息：: 1.       性状：白色结晶。
2.       密度（g/mL,25/4℃）：未确定
3.       相对蒸汽密度（g/mL,空气=1）：溶于碱溶液，不溶于水、乙醇和乙醚
4.       熔点（ºC）：235
5.       沸点（ºC,常压）：未确定
6.       沸点（ºC,5.2kPa）：未确定
7.       折射率：未确定
8.       闪点（ºC）：未确定
9.       比旋光度（º）：-4.45 (546nm) (EtOH/NaOH)
10.    自燃点或引燃温度（ºC）：未确定
11.    蒸气压（kPa,25ºC）：未确定
12.    饱和蒸气压（kPa,60ºC）：
13.    燃烧热（KJ/mol）：未确定
14.    临界温度（ºC）：未确定
15.    临界压力（KPa）：未确定
16.    油水（辛醇/水）分配系数的对数值
17.    爆炸上限（%,V/V）：未确定
18.    爆炸下限（%,V/V）：未确定
19.    溶解性：。未确定

L-甲状腺素安全信息

海关代码：: 2942000000
WGK_Germany：: 3
德国有关水污染物质的分类清单
危险类别码：: R20/21/22
安全说明：: S22-S24/25
RTECS号：: YP2833500
安全标志：: S22:不要吸入粉尘。
S24/25:防止皮肤和眼睛接触。
危险标志：: Xn:Harmful

L-甲状腺素毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :: YP2833500

CHEMICAL NAME :: L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-

CAS REGISTRY NUMBER :: 51-48-9

BEILSTEIN REFERENCE NO. :: 2228515

LAST UPDATED :: 199709

DATA ITEMS CITED :: 15

MOLECULAR FORMULA :: C15-H11-I4-N-O4

MOLECULAR WEIGHT :: 776.87

WISWESSER LINE NOTATION :: QVYZ1R CI EI DOR DQ CI EI

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 63 ug/kg

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions Cardiac - pulse rate increase, without fall in BP

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 400 ug/kg/2D-I

TOXIC EFFECTS :: Behavioral - coma Cardiac - arrhythmias (including changes in conduction)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2 mg/kg/10D-I

TOXIC EFFECTS :: Liver - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - monoamine oxidase Biochemical - Metabolism (Intermediary) - effect on mitochondrial function

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 26250 ug/kg

SEX/DURATION :: female 1-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - eye/ear

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1400 ug/kg

SEX/DURATION :: female 16-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 410 mg/kg

SEX/DURATION :: female 3 week(s) pre-mating female 1-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 450 ug/kg

SEX/DURATION :: female 7-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 8160 ug/kg

SEX/DURATION :: female 7 day(s) pre-mating - 5 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Maternal Effects - postpartum

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 600 ug/kg

SEX/DURATION :: female 19-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 12 mg/kg

SEX/DURATION :: male 6 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 12 mg/kg

SEX/DURATION :: female 9-11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

MUTATION DATA

TEST SYSTEM :: Rodent - rat

DOSE/DURATION :: 6250 ug/kg/2D (Continuous)

REFERENCE :: BEXBAN Bulletin of Experimental Biology and Medicine (English Translation). Translation of BEBMAE. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) V.41- 1956- Volume(issue)/page/year: 72,942,1971 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M0234 No. of Facilities: 68 (estimated) No. of Industries: 1 No. of Occupations: 6 No. of Employees: 2770 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M0234 No. of Facilities: 717 (estimated) No. of Industries: 4 No. of Occupations: 9 No. of Employees: 10666 (estimated) No. of Female Employees: 7298 (estimated)

毒理学数据：: 1、急性毒性：男人经口TDLo：63ug/kg；女人经口TDLo：400ug/kg/2D-I

L-甲状腺素 MSDS

Name:	L-Thyroxine 99% Material Safety Data Sheet
Synonym:	None Known
CAS:	51-48-9

Section 1 - Chemical Product MSDS Name:L-Thyroxine 99% Material Safety Data Sheet
Synonym:None Known

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
51-48-9	L-Thyroxine	99%	200-101-1

Hazard Symbols: XN
Risk Phrases: 20/21/22

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated.Light sensitive.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid if irritation develops or persists. Wash clothing before reuse. Flush skin with plenty of soap and water.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Store protected from light.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Hormones and antibiotics room. Store protected from light.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Good general ventilation should be sufficient to control airborne levels. Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Exposure Limits CAS# 51-48-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Decomposes
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Insoluble in water
Specific Gravity/Density: Not available.
Molecular Formula: C15H11I4NO4
Molecular Weight: 776.6993

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents, strong bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen, hydrogen iodide.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 51-48-9: YP2833500 LD50/LC50:
Not available.
Carcinogenicity:
L-Thyroxine - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 51-48-9: 1
Canada
CAS# 51-48-9 is listed on Canada's DSL List.
CAS# 51-48-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 51-48-9 is listed on the TSCA inventory.

SECTION 16 - ADDITIONAL INFORMATION
N/A

L-甲状腺素分子结构与计算化学数据

分子结构数据

1、摩尔折射率：125.44

2、摩尔体积（cm³/mol）：294.7

3、等张比容（90.2K）：880.4

4、表面张力（dyne/cm）：79.6

5、极化率（10-24cm3）：49.73

计算化学数据

1.疏水参数计算参考值（XlogP）:2.4

2.氢键供体数量:3

3.氢键受体数量:5

4.可旋转化学键数量:5

5.互变异构体数量:2

6.拓扑分子极性表面积92.8

7.重原子数量:24

8.表面电荷:0

9.复杂度:420

10.同位素原子数量:0

11.确定原子立构中心数量:1

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

L-甲状腺素上游产品

3,5-二碘-L-甲状腺素 DL-甲状腺素 N-乙酰基-3,5-二碘-L-酪氨酸; 2-(乙酰氨基)-3-(4-羟基-3,5-二碘苯基)丙酸 L-酪氨酸 L-酪氨酸甲酯

L-甲状腺素下游产品

N-Acetyl L-Thyroxine 碘塞罗宁 L-甲状腺氨酸

L-甲状腺素

L-甲状腺素制备方法及用途

制备方法

合成制备方法

用途简介

用途

L-甲状腺素物化性质

L-甲状腺素安全信息

L-甲状腺素毒理性

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

L-甲状腺素 MSDS

L-甲状腺素分子结构与计算化学数据

分子结构数据

计算化学数据

L-甲状腺素上游产品

L-甲状腺素下游产品

推荐供应商

湖北云镁科技有限公司

L-甲状腺素

沧州恩科医药科技有限公司

L-甲状腺素

湖北鑫红利化工有限公司

甲状腺素

上海吉至生化科技有限公司

(S)-2-氨基-3-(4-(4-羟基-3,5-二碘苯氧基)-3,5-二碘苯基)丙酸

湖北臻博化工有限公司

L-甲状腺素

北京百灵威科技有限公司

L-甲状腺素 116132

西安瑞盈生物科技有限公司

L-甲状腺素

上海源叶生物科技有限公司

L-甲状腺素

武汉东康源科技有限公司

L-甲状腺素

南京晟宁医药科技有限公司

L-甲状腺素

L-甲状腺素

L-甲状腺素 制备方法及用途

制备方法

合成制备方法

用途简介

用途

L-甲状腺素 物化性质

L-甲状腺素 安全信息

L-甲状腺素 毒理性

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

L-甲状腺素 MSDS

L-甲状腺素 分子结构与计算化学数据

分子结构数据

计算化学数据

L-甲状腺素 上游产品

L-甲状腺素 下游产品

推荐供应商

湖北云镁科技有限公司

L-甲状腺素

沧州恩科医药科技有限公司

L-甲状腺素

湖北鑫红利化工有限公司

甲状腺素

上海吉至生化科技有限公司

(S)-2-氨基-3-(4-(4-羟基-3,5-二碘苯氧基)-3,5-二碘苯基)丙酸

湖北臻博化工有限公司

L-甲状腺素

北京百灵威科技有限公司

L-甲状腺素 116132

西安瑞盈生物科技有限公司

L-甲状腺素

上海源叶生物科技有限公司

L-甲状腺素

武汉东康源科技有限公司

L-甲状腺素

南京晟宁医药科技有限公司

L-甲状腺素

L-甲状腺素制备方法及用途

L-甲状腺素物化性质

L-甲状腺素安全信息

L-甲状腺素毒理性

L-甲状腺素分子结构与计算化学数据

L-甲状腺素上游产品

L-甲状腺素下游产品